Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Trimmed by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 31,066 shares of the medical research company's stock after selling 1,205 shares during the quarter. Thermo Fisher Scientific comprises about 2.8% of Arcadia Investment Management Corp MI's holdings, making the stock its 11th largest position. Arcadia Investment Management Corp MI's holdings in Thermo Fisher Scientific were worth $15,458,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TMO. Cypress Advisory Group LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $253,000. Intact Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after buying an additional 660 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Finally, Hancock Whitney Corp boosted its stake in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock worth $2,802,000 after purchasing an additional 30 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $500.00 to $460.00 in a research note on Tuesday. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $601.05.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $6.70 during mid-day trading on Wednesday, reaching $419.47. The company had a trading volume of 2,735,091 shares, compared to its average volume of 1,985,486. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $158.35 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.23 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The stock's 50-day simple moving average is $409.11 and its two-hundred day simple moving average is $478.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.11 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.